„This is a randomised, phase III, non-inferiority trial evaluating radiation therapy (RT) versus observation (no RT) following breast conserving surgery in patients who are planned to receive adjuvant endocrine therapy for stage I breast cancer of luminal A subtype and Risk of Recurrence (ROR) score ≤60 characterised using Prosigna (PAM50) Assay.”

    Lead Trial Coordinator
    Holly Shaw

    Trial Coordinator
    Meredith Kissel

    IBCSG Data Management Center/FSTRF
    4033 Maple Road
    Amherst, New York 14226 USA
    Phone: +1 716 834 0900
    Fax: +1 716 833 3990

    This email address is being protected from spambots. You need JavaScript enabled to view it.


    Targeted Accrual

    International Breast
    Cancer Study Group

    Effingerstrasse 40
    3008 Bern, Switzerland

    Phone: +41 31 511 94 00
    E-mail: ibcsgcc@ibcsg.org

    Member Login